pulmonary TB

pulmonary TB

Pulmonary tuberculosis, see there.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
The treatment combination was approved to treat adult patients with extensively drug-resistant, treatment-intolerant, or nonresponsive multidrug-resistant pulmonary TB. Dosing involves 200 mg of Pretomanid tablets orally once daily for 26 weeks, 400 mg of bedaquiline orally once daily for two weeks followed by 200 mg three times per week for 24 weeks, and 1,200 mg of oral linezolid daily for up to 26 weeks.
Previous treatment for TB is considered as a strongest risk factor for the development of MDR-TB.8 Previous treatment or category II pulmonary TB includes those patients who had failed previous TB treatment, relapsed after treatment or defaulted during previous treatment.9 Since such patients have already been exposed to anti-tuberculosis agents they are at high risk for developing multi-drug resistant strains.
In cases where sputum was not produced, patients were identified as pulmonary TB (PTB) cases based on strong radiological findings and clinical correlation.
The survey, which just kick-started, will also try to assess health seeking behaviour for TB related symptoms of individuals aged 15 and above and will also determine point prevalence of bacteriologically confirmed pulmonary TB in the country.
Despite these data, research on extrapulmonary TB is limited, possibly because extrapulmonary TB is less transmissible than pulmonary TB (6-8).
TB-PCR and drug resistance pattern in BALF in smear-negative active pulmonary TB. Int J Tuberc Lung Dis.
If left untreated, pulmonary TB will severely weaken an infected person, leaving them emaciated.
This agreement comes as the New England Journal of Medicine published the results of a clinical study conducted by Aeras in collaboration with GSK (GSK), evaluating GSK's investigational TB vaccine candidate, M72/AS01E The Phase IIb efficacy study showed that the vaccine protected against active pulmonary TB disease, with an overall vaccine efficacy of 54 percent.
Age, symptomatology, non-CKD risk factors like smoking, alcoholism, previous history of pulmonary TB, presence of diabetes mellitus, other infections like HCV and in case of post-transplant patients, use of induction therapy, any graft dysfunction etc.
However, despite there are diagnostic problems, treatment success for pulmonary TB in the country is as high as 95 per cent, sources said.
[9,10] In addition, the prevalence of PHT among individuals who have been treated for pulmonary TB but who have minimal fibrotic parenchymal disease is also not known.